The von Willebrand factor collagen-binding activity assay: Clinical application

被引：0
作者：
Kallas A. [1 ]
Talpsep T. [2 ]
机构：
[1] Department of Pharmacy, University of Tartu, Tartu, 51014
[2] Institute of Molecular and Cell Biology, University of Tartu, Tartu, 51010
来源：
Annals of Hematology | 2001年 / 80卷 / 8期
关键词：
Collagen; Factor VIII; Factor VIII concentrate; Von Willebrand factor; Von Willebrand's disease;
D O I：
10.1007/s002770100329
中图分类号：
学科分类号：
摘要：
A collagen type III based collagen-binding assay was developed for measuring the functional activity of the von Willebrand factor. The assay had a low coefficient of variance (4.8%) for normal values under optimized conditions. The results of the collagen-binding activity (CBA) assay correlated with ristocetin cofactor activity tested in normal plasma samples (n=29). We found that the CBA of blood group O is lower than that of other blood groups. The test was used for the diagnosis of von Willebrand's disease (VWD) and for estimating the response to treatment with DDAVP (1-deamino-D-arginine-8 vasopressin) and factor VIII concentrate. A mean ratio of VWF antigen (VWF:Ag) to CBA of 1.5 indicated type 1 and of 2.7 indicated type 2 VWD. The increase in the collagen-binding activity of VWF released in type 1 VWD patients (n=7) after treatment with DDAVP was higher than the increase in the VWF antigen; this is characteristic of very high multimers with greater functional activity. Factor VIII concentrate Koate-HP (Bayer) administered to a patient with VWD type 3 had a mean residence time of 12.6 h for VWF:Ag and 11.2 h for CBA. These findings suggest that the collagen-binding assay is a useful test for measuring the functional activity of VWF in plasma samples, factor VIII concentrates, as well as for estimating the outcome of treatment.
引用
收藏
页码：466 / 471
页数：5
相关论文
共 29 条
  • [1] Carlebjork G., Blomback M., Blomstedt M., Akerblom O., Screening of factor VIII:C levels in blood donors, Vox Sang, 51, pp. 306-309, (1986)
  • [2] Casonato A., Pontara E., Bertomoro A., Zucchetto S., Zerbinati P., Girolami A., Abnormal collagen binding activity of 2A von Willebrand factor: Evidence that the effect depends only on the lack of large multimers, J Lab Clin Med, 129, pp. 251-259, (1997)
  • [3] Casonato A., Pontara E., Bertomoro A., Sartorello F., Girolami A., Which assay is the most suitable to investigate von Willebrand factor functional activity?, Thromb Haemost, 81, pp. 994-995, (1999)
  • [4] Cruz M.A., Yuan H., Lee J.R., Wise R.J., Handin R.I., Interaction of the von Willebrand factor (VWF) with collagen, J Biol Chem, 270, pp. 10822-10827, (1995)
  • [5] Human coagulation factor VIII, freeze-dried, European Pharmacopoeia, SUPPL. 2001, pp. 951-953, (2000)
  • [6] Evans R.M., Austen D.E., Assay of ristocetin co-factor using fixed platelets and a platelet counting technique, Br J Haematol, 37, pp. 289-294, (1977)
  • [7] Favaloro E.J., Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrand's disease (VWD), and discrimination of VWF subtypes, depends on collagen source, Thromb Haemost, 83, pp. 127-135, (2000)
  • [8] Favaloro E.J., Henniker A., Facey D., Hertzberg M., Discrimination of von Willebrand's disease (VWD) subtypes: Direct comparison von Willebrand factor collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems, Thromb Haemost, 84, pp. 541-547, (2000)
  • [9] Fischer B.E., Thomas K.B., Dorner F., Collagen covalently immobilized onto plastic surfaces simplifies measurement of von Willebrand factor-collagen binding activity, Ann Hematol, 76, pp. 159-166, (1998)
  • [10] Furlan M., Robles R., Affolter D., Meyer D., Baillod P., Lammle B., Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers, Proc Natl Acad Sci USA, 90, pp. 7503-7507, (1993)
123